People · Operator

Wayne Comper

Named in public records as an officer, director or promoter · active 2010–2012 · Biotechnology

1
Companies
4
Filings
$90.9M
Combined raised · real
Single
Operator type
Companies
CompanyRoleSectorStageRaised · realValue · estTied
Exosome Diagnostics, Inc.BiotechnologySeries B$90.9M$1.2B2010
Operator network

Wayne Comper at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.

Georg Nebgen · 5 companies · 1 sharedGeorg NebgenWilliam Kelly · 5 companies · 1 sharedWilliam KellyDavid Okrongly · 4 companies · 1 sharedDavid OkronglyJohn Boyce · 4 companies · 1 sharedJohn BoyceJames McCullough · 3 companies · 1 sharedJames McCulloughSara Barrington · 3 companies · 1 sharedSara BarringtonGeert-Jan Mulder · 2 companies · 1 sharedGeert-Jan MulderJoseph Boystak · 2 companies · 1 sharedJoseph BoystakKapil Dhingra · 2 companies · 1 sharedKapil DhingraPeter Johann · 2 companies · 1 sharedPeter JohannThomas McLain · 2 companies · 1 sharedThomas McLainDhingra Kapil · 1 companies · 1 sharedDhingra KapilGreg Zdechlik · 1 companies · 1 sharedGreg ZdechlikJoseph Slattery · 1 companies · 1 sharedJoseph SlatterySteven Soignet · 1 companies · 1 sharedSteven SoignetExosome Diagnostics, Inc. · $90.9M raisedExosome Diagnostics, …Wayne ComperWC
Wayne Comper Company Co-operator (ring = serial)Hover to isolate ties · click to open
Co-operators (shared boards)

People named alongside Wayne Comper on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.

OperatorSharedTheir companies
William Kelly15
Georg Nebgen15
David Okrongly14
John Boyce14
James McCullough13
Sara Barrington13
Joseph Boystak12
Kapil Dhingra12
Thomas McLain12
Peter Johann12
Geert-Jan Mulder12
Greg Zdechlik11
Steven Soignet11
Dhingra Kapil11
Joseph Slattery11

People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.